a certificate dated 1st April, 2025 under Regulations 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2025 received from M/S Purva Sharegistry India Pvt. Ltd. , Registrar ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma Ltd has submitted to BSE a compliance certificate dated 1st April, 2025, received from its Registrar and Share Transfer Agent, Purva Sharegistry India Pvt. Ltd., under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate covers the quarter ended 31st March, 2025 and confirms that all share certificates received for dematerialization during the quarter were duly verified, confirmed or rejected, and the corresponding entries updated in the register of members within the required timelines. One dematerialization entry is visible: shareholder Rameshchandra Dayabhai Hansaliya had 2,500 shares dematerialized on 26 February, 2025. The filing is a routine regulatory submission with no business or financial details.
This is a standard procedural compliance filing and has no material impact on the company's operations, financials, or share price. It simply reassures investors that the company's share transfer and dematerialization processes are functioning properly.